25 October 2018
We presented a novel, predictive model of functional decline at CTAD 2018. The model suggests that CANTAB PAL and SWM provide essential screening information when recruiting patients with amnestic mild cognitive impairment into Alzheimer’s disease clinical trials.
24 October 2018
At CTAD 2018 we shared our new data on why a Bayesian approach is best to describe normative cognitive performance, especially when making scientifically robust comparisons to neurologically impaired groups.
16 October 2018
We caught up with University of Calgary Postdoctoral Research Fellows, Dr Matiram Pun and Dr Veronica Guadagni, to discuss the role of CANTAB in their recent research paper on how different exposures to high altitude affect cognitive function.
15 October 2018
To date, no effective drugs have been developed to address cognitive dysfunction in schizophrenia. Here we will highlight the three main methodological challenges which may be contributing to these high failure rates, and propose potential practical solutions to these problems.
8 October 2018
We caught up with Shinwon Park at Ewha Womens University to discuss their experiences of updating their longitudinal studies from tablet-only CANTAB Eclipse to the cloud-based CANTAB Connect Research platform.
4 October 2018
A negative, perceptual bias is associated with the onset and maintenance of mood disorders, and is therefore a therapeutic avenue of interest. Here we will discuss the launch of an objective assessment of emotional bias as a potential biomarker of mood.